Teva And Alvotech Confirm Quallent Deal On US Adalimumab
Follows Announcement By Cigna’s Evernorth Of $0 Out-Of-Pocket Scheme For Biosimilar
Teva and Alvotech have confirmed deductions that it is their recently-approved 100mg/ml adalimumab biosimilar that will be used by Cigna’s Evernorth as part of a recently announced private-label deal involving Evernorth’s Quallent Pharmaceuticals.
